Anupam Rasayan in Focus After Acquiring Up to 48% Stake in Bliss GVS Pharma

Synopsis: Anupam Rasayan India Limited, a leading specialty chemicals company, announced on May 23, 2026, that it has signed a definitive agreement to acquire a 43.3% – 48.2% equity stake in Bliss GVS Pharma Limited, along with an open offer to public shareholders a major deal that signals Anupam’s shift toward becoming an integrated life sciences and pharmaceutical platform.

In a regulatory filing submitted on May 23, 2026, Anupam Rasayan India Limited announced a major acquisition. The company has signed a definitive agreement to acquire between 43.3% and 48.2% equity stake in Bliss GVS Pharma Limited, a Mumbai-based pharmaceutical formulations company, along with an open offer to public shareholders of Bliss GVS Pharma. The filing was signed by Managing Director Anand Desai.

Shares of Anupam Rasayan India Limited traded slightly lower on May 25, 2026, falling nearly 1% to Rs. 1,353 during intraday trade compared to the previous close of Rs. 1,366.10. The stock touched an intraday high of Rs. 1,390 and a low of Rs. 1,341.30, with traded value crossing Rs. 46 crore. The company currently has a market capitalisation of around Rs. 15,404 crore and trades at a P/E ratio of nearly 70.

The acquisition will be funded through a mix of Rs. 300 crore term loan and a non-controlling, non-voting equity instrument for the remaining consideration. This financing structure helps reduce immediate equity dilution for existing shareholders while allowing Anupam to secure a controlling stake in Bliss GVS.

This deal marks a major strategic shift for Anupam Rasayan. Until now, the company mainly operated as a custom synthesis and specialty chemicals manufacturer supplying pharma and agrochemical companies at the upstream level. With the acquisition of Bliss GVS Pharma, Anupam is now moving downstream into finished pharmaceutical formulations, creating a presence across the full pharma value chain from Key Starting Materials (KSMs) to finished medicines sold to patients.

Bliss GVS Pharma brings highly complementary strengths to the business. Founded in 1984 and listed on both NSE and BSE, Bliss GVS operates manufacturing facilities in Maharashtra and Daman that are approved by US FDA, WHO-GMP, and EU-GMP. The company is globally known for its strong position in suppositories and pessaries, a niche but profitable dosage segment where it owns one of the world’s largest product portfolios. Its branded formulations business includes over 150 products across antimalarial, antifungal, antibacterial, anti-inflammatory, and women’s healthcare categories, with brands like Lonart, Funbact, and Lofnac having strong presence across Africa, Asia, and Latin America.

Building a Global Life Sciences Platform

For Anupam Rasayan, the strategic fit appears strong. The company currently operates eight manufacturing facilities six in Gujarat, one in Tamil Nadu, and one in the United States with total installed capacity exceeding 2,00,000 MT. Its expertise in complex chemical synthesis and advanced chemistry now gets a forward integration opportunity through Bliss GVS’s formulation manufacturing and distribution network.

The deal also strengthens Anupam’s international presence, especially in Europe and the US, where Bliss GVS already has approvals and distribution reach. This also complements Anupam’s earlier Jayhawk acquisition in the US, which helped establish its North American footprint.

Management believes the combined business can unlock synergies across product offerings, supply chains, regulated market access, and future innovation pipelines. For investors, the long-term story is the creation of a vertically integrated specialty pharma and chemicals platform, a business model that often attracts higher valuation multiples compared to standalone specialty chemical companies.

Market Implications

The market is likely to track this acquisition closely because it significantly changes Anupam Rasayan’s business profile from a largely B2B specialty chemicals company to a more integrated pharma player with B2C exposure. The financing structure using debt and non-voting equity appears shareholder-friendly in the short term, although the additional Rs. 300 crore debt will remain an important factor to monitor, especially in a higher interest rate environment. Anupam currently serves more than 185 domestic and international customers across agrochemicals, personal care, and pharmaceutical segments.

About Anupam Rasayan India Limited

Incorporated in 1984 and listed on NSE and BSE, Anupam Rasayan India Limited is one of India’s leading custom synthesis and specialty chemicals companies. Headquartered in Surat, Gujarat, the company operates across Life Science Specialty Chemicals and other specialty chemical segments including polymer additives. With eight manufacturing facilities and installed capacity of over 2,00,000 MT, Anupam serves a diversified base of more than 185 domestic and global customers.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Anupam Rasayan in Focus After Acquiring Up to 48% Stake in Bliss GVS Pharma appeared first on Trade Brains.